MARKET

IRWD

IRWD

Ironwood
NASDAQ
3.730
+0.230
+6.57%
Closed 19:53 12/04 EST
OPEN
3.720
PREV CLOSE
3.730
HIGH
3.755
LOW
3.520
VOLUME
1.78M
TURNOVER
0
52 WEEK HIGH
5.13
52 WEEK LOW
0.5271
MARKET CAP
606.79M
P/E (TTM)
26.53
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at IRWD last week (1124-1128)?
Weekly Report · 4d ago
CMS Slashes Prices Of 15 Major Drugs - Here's Why Pharma Valuations Won't Suffer
Seeking Alpha · 11/26 21:58
Ironwood Pharmaceuticals: Today's Gains Seem Sustainable After Disastrous First Half Of 2025
Seeking Alpha · 11/26 21:03
BUZZ-U.S. STOCKS ON THE MOVE-Nucor, Natgas companies, health insurers
Reuters · 11/26 18:48
Urban Outfitters, Arrowhead Pharmaceuticals, Petco Health and Wellness And Other Big Stocks Moving Higher On Wednesday
Benzinga · 11/26 16:30
BUZZ-U.S. STOCKS ON THE MOVE-Robinhood Markets, Oracle, Grindr
Reuters · 11/26 15:41
Ironwood price target raised to $3.80 from $1.70 at Craig-Hallum
TipRanks · 11/26 15:10
Analysts Conflicted on These Healthcare Names: Terns Pharmaceuticals (TERN) and Ironwood Pharma (IRWD)
TipRanks · 11/26 15:10
More
About IRWD
Ironwood Pharmaceuticals, Inc. is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI), and rare diseases. It is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The Company is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.

Webull offers Ironwood Pharmaceuticals, Inc. stock information, including NASDAQ: IRWD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IRWD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IRWD stock methods without spending real money on the virtual paper trading platform.